Popular Heartburn and Ulcer Drugs Linked to an Increased Risk of Death

Sign Up For My 7-Day Accelerate Your Health Challenge!

Discover the tools and techniques that will empower you to immediately take charge of your health and well-being in ways you never knew were possible.

I agree to have my personal information transfered to AWeber ( more information )

No spam guarantee.

Study shows that long-term use of a class of drugs widely prescribed to treat heartburn, ulcers and other gastrointestinal problems, are linked to an increased risk of death.

Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. These drugs can be easily obtained over the counter. They are sold under brand names like Prilosec, Nexium and Prevacid. Now, a new study from Washington University School of Medicine in St. Louis shows that longtime use of the drugs also is associated with an increased risk of death.

Millions of Americans take proton pump inhibitors which are widely prescribed to treat heartburn, ulcers and other gastrointestinal problems. The drugs also are available over the counter under brand names that include Prevacid, Prilosec and Nexium.

For the study, the researchers examined medical records of some 275,000 users of PPIs and nearly 75,000 people who took another class of drugs – known as H2 blockers – to reduce stomach acid. The research is published online July 3 in the journal BMJ Open.

“No matter how we sliced and diced the data from this large data set, we saw the same thing: There’s an increased risk of death among PPI users,” said senior author Ziyad Al-Aly, MD, an assistant professor of medicine. “For example, when we compared patients taking H2 blockers with those taking PPIs for one to two years, we found those on PPIs had a 50 percent increased risk of dying over the next five years. People have the idea that PPIs are very safe because they are readily available, but there are real risks to taking these drugs, particularly for long periods of time.”

Both PPIs and H2 blockers are prescribed for serious medical conditions such as upper gastrointestinal tract bleeding, gastroesophageal reflux disease and esophageal cancer. Over-the-counter PPIs are most often used for heartburn and indigestion.

PPIs have become one of the most commonly used classes of drugs in the United States with 15 million monthly prescriptions in 2015 for Nexium alone, according to WebMD.

A kidney doctor by profession, Al-Aly has previously published studies linking PPIs linking to kidney disease and other researchers have shown an association with other health problems. Al-Aly, first author Yan Xie, PhD, a data scientist, and colleagues reasoned that since each of these side effects carries a small risk of death, together they may affect the mortality rate of PPI users.

To find out, the researchers sifted through millions of de-identified veterans’ medical records in a database maintained by the U.S. Department of Veterans Affairs. They identified 275,933 people who had been prescribed a PPI and 73,355 people prescribed an H2 blocker between October 2006 and September 2008, and noted how many died and when over the following five years. The database did not include information on cause of death.

Death Risk Increased by 25%

Al-Aly and colleagues found a 25 percent increased risk of death in the PPI group compared with the H2 blocker group. The researchers calculate that, for every 500 people taking PPIs for a year, there is one extra death that would not have otherwise occurred. Given the millions of people who take PPIs regularly, this could translate into thousands of excess deaths every year, Al-Aly said.

The researchers also calculated the risk of death in people who were prescribed PPIs or H2 blockers despite not having the gastrointestinal conditions for which the drugs are recommended. Here, the researchers found that people who took PPIs had a 24 percent increased risk of death compared with people taking H2 blockers.

Further, the risk rose steadily the longer people used the drugs. After 30 days, the risk of death in the PPI and H2 blocker groups was not significantly different, but among people taking the drugs for one to two years, the risk to PPI users was nearly 50 percent higher than that of H2 blocker users.

Although the recommended treatment regimen for most PPIs is short – two to eight weeks for ulcers, for example – many people end up taking the drugs for months or years.

“A lot of times people get prescribed PPIs for a good medical reason, but then doctors don’t stop it and patients just keep getting refill after refill after refill,” Al-Aly said. “There needs to be periodic re-assessments as to whether people need to be on these. Most of the time, people aren’t going to need to be on PPIs for a year or two or three.”

As compared with the H2 blocker group, people in the PPI group were older (64 years old, on average, versus 61) and also somewhat sicker, with higher rates of diabetes, hypertension and cardiovascular disease. But these differences cannot fully account for the increased risk of death since the risk remained even when the researchers statistically controlled for age and illness.

Over-the-counter PPIs contain the same chemical compounds as in prescription PPIs, just at lower doses, and there is no way to know how long people stay on them. The Food and Drug Administration recommends taking PPIs no longer than four weeks before consulting a doctor.

Al-Aly emphasizes that deciding whether to take a PPI requires a risk-benefit calculation.

“PPIs save lives,” Al-Aly said. “If I needed a PPI, I absolutely would take it. But I wouldn’t take it willy-nilly if I didn’t need it. And I would want my doctor to be monitoring me carefully and take me off it the moment it was no longer needed.”

About the Study

The research team studied the medical records of about 275,000 PPI users and upwards of 75,000 people who took a separate class of drugs referred to as H2 blockers that minimize stomach acid. The findings were recently published in BMJ Open. H2 blockers and PPIs are prescribed for an array of serious medical conditions like esophageal cancer, gastrointestinal tract bleeding and gastroesophageal reflux disease.

The data from the above-referenced data set was analyzed in-depth. A common theme emerged: PPI users had a heightened risk of death. As an example, when the researchers compared patients who took H2 blockers with patients who took PPIs across one or a couple years, it was determined that those who took PPIs had a 50% higher risk of perishing across the next half-decade. The average person assumes PPIs are safe as they can be obtained quite easily over the counter to treat heartburn and/or indigestion. Yet there are serious risks to taking such drugs, especially if they are consumed across extensive periods of time. Unfortunately, most people are unaware of these risks. This is a major problem as PPIs have quickly become one of the most commonly used drug classes in the country. As an example, about 15 million monthly prescriptions for Nexium were written in 2015.

The study’s authors believe the combined side effects of PPIs might affect mortality rate. To determine if this is the case, the researchers sorted through millions of veterans’ medical records within a database provided by the United States Department of Veterans Affairs. They pinpointed over 275,000 individuals who were prescribed a PPI and more than 73,000 individuals prescribed an H2 blocker across a time span of October of 2006 and September of 2008. The researchers determined how many of these individuals perished and the exact date of death across a five-year period.

The Results

The researchers determined there is a 25 percent higher chance of death in the PPI group when contrasted against those in the H2 blocker group. The research team determined that for each 500 people consuming PPIs for a single year, there is a single additional death that otherwise would not have occurred. This is important as millions of people use PPIs on a regular basis. This massive scale means PPI use has the potential to cause thousands of deaths every single year.

The researchers also determined the risk of death in those who were prescribed H2 blockers or PPIs even though they did not have gastrointestinal conditions for which these alleged remedies are recommended. In such instances, the research team determined those who took PPIs had nearly a one-quarter increase in the chance of death when compared to those who took H2 blockers. This risk steadily increased with the amount of time people used the drugs. After 30 days of use, the risk of death in H2 blocker and PPI groups was similar. However, those who took PPI for a one to two years endured a nearly 50% hike in odds of death compared to those who used H2 blockers.

Leave a Reply

Your email address will not be published. Required fields are marked *

Name

Email

Website

Elaine Ferguson, MD is a pioneer in the field of integrative and holistic medicine. She’s a graduate of Brown University, Duke University School of Medicine and completed her post-graduate training at the University of Chicago. During her trailblazing career she served as the founding medical director of the nation’s first Independent Practice Association (IPA) of chiropractors to provide primary care in a managed care setting, and practiced at the Cancer Treatment Centers of America. Also, Dr. Ferguson taught mind-body medicine at one of the nation’s first graduate level holistic medicine programs. She is the host of the acclaimed PBS pledge special SuperHealing Secrets currently airing nationwide, and has written several books, including the international bestseller SuperHealing: Engaging Your Mind, Body, and Spirit to Create Optimal Health and Well-Being. As a wellness consultant, and speaker, she’s lectured extensively at conferences, universities and medical schools, consulted with businesses, government agencies, not-for-profits, faith based organizations, and testified on a Congressional alternative medicine panel.

Disclaimer
The information contained on this website is for informational purposes only. It has not been evaluated by the FDA. The information is not intended to prevent, treat, diagnose or cure any illness or disease. All material provided on www.drelaine.com is only for the education of the reader. You should always consult with your physician or other licensed health care provider with any questions you may have regarding a medical condition regarding your health and/or medical condition, and before undertaking any changes in your exercise, eating habits, diet, physical therapy or other health program. This website does not recommend self-management of one’s health care. Images, text and logic are copyright protected. All rights are explicitly reserved without prejudice, and no part of this website may be reproduced except by written consent. Copyright. All rights remain in force. Removing this notice forfeits all rights to recourse.